KinetiX-VBE

Smarter Bioequivalence Analysis. AI-Assisted Scientific Interpretation.

Kinetix Bioequivalence Software helps scientific, regulatory, and pharmaceutical development teams analyze bioequivalence studies with greater efficiency, technical precision, and scientific clarity. The platform was built to support bioequivalence study assessment, pharmacokinetic analysis, formulation comparison, result interpretation, and the creation of structured scientific reports. The software transforms complex pharmacokinetic data into clear conclusions, supporting decision-making in generic drug projects, modified formulations, biowaivers, pharmaceutical development, and regulatory submissions. Beyond traditional bioequivalence analysis, Kinetix Bioequivalence Software can be integrated with PBPK/PBBM modeling tools, connecting in vitro data, dissolution, formulation performance, and systemic exposure. This integration reduces analysis time and cost, lowers dependence on repetitive experimental studies, and supports modern development strategies based on modeling and simulation. The platform can also be integrated with artificial intelligence for scientific interpretation of results, critical factor identification, risk assessment, technical conclusion generation, and automatic scientific report writing. This means users do not only run calculations, but also receive support to understand what the results mean and communicate the evidence clearly and robustly. The software also includes computational optimizers capable of creating, testing, and comparing multiple simulation scenarios. Depending on study configuration, the system can generate and execute up to 1,000 trials in approximately 30 seconds, allowing teams to rapidly explore different conditions, parameters, and formulation strategies. With Kinetix Bioequivalence Software, pharmaceutical teams can accelerate analyses, reduce costs, increase scientific robustness, and make decisions with greater confidence. Analyze faster. Predict smarter. Report with confidence.